Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Auerbach, H. Ballard, J. Trout, M. McIlwain, A. Ackerman, H. Bahrain, S. Balan, L. Barker, J. Rana (2004)
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 7
B. Leyland-Jones, V. Semiglazov, M. Pawlicki, T. Pieńkowski, S. Tjulandin, G. Manikhas, A. Makhson, A. Roth, D. Dodwell, J. Baselga, M. Biakhov, K. Valuckas, E. Voznyi, Xiangyang Liu, E. Vercammen (2005)
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
T. Ganz (2003)
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.Blood, 102 3
D. Cella, M. Zagari, C. Vandoros, D. Gagnon, H. Hurtz, J. Nortier (2003)
Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 2
C. Hudis, S. Belle, José Chang, K. Muenstedt (2004)
rHuEPO and Treatment Outcomes: the Clinical ExperienceOncologist, 9
W. Jelkmann (2004)
Molecular biology of erythropoietin.Internal medicine, 43 8
J. Caro, M. Salas, A. Ward, G. Goss (2001)
Anemia as an independent prognostic factor for survival in patients with cancerCancer, 91
C. Bennett, S. Luminari, A. Nissenson, M. Tallman, S. Klinge, N. McWilliams, J. McKoy, Benjamin Kim, E. Lyons, S. Trifilio, D. Raisch, A. Evens, T. Kuzel, G. Schumock, S. Belknap, F. Locatelli, J. Rossert, N. Casadevall (2004)
Pure red-cell aplasia and epoetin therapy.The New England journal of medicine, 351 14
M. Auerbach, H. Ballard, J. Glaspy (2007)
Clinical update: intravenous iron for anaemiaThe Lancet, 369
S. Ross, K. Fahrbach, D. Frame, R. Scheye, J. Connelly, J. Glaspy (2003)
The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review.Clinical therapeutics, 25 6
J. Vansteenkiste, R. Pirker, B. Massutí, F. Barata, A. Font, M. Fiegl, S. Siena, J. Gateley, D. Tomita, A. Colowick, J. Musil (2002)
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.Journal of the National Cancer Institute, 94 16
H. Ludwig, S. Belle, P. Barrett-Lee, G. Birgegard, C. Bokemeyer, P. Gascón, P. Kosmidis, M. Krzakowski, J. Nortier, P. Olmi, M. Schneider, D. Schrijvers (2004)
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.European journal of cancer, 40 15
G. Lyman, J. Glaspy (2006)
Are there clinical benefits with early erythropoietic intervention for chemotherapy‐induced anemia?Cancer, 106
M. Machtay, T. Pajak, M. Suntharalingam, G. Shenouda, D. Hershock, D. Stripp, A. Cmelak, A. Schulsinger, K. Fu (2007)
Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).International journal of radiation oncology, biology, physics, 69 4
Gary Lyman, Ernst Berndt, J. Kallich, M. Erder, William Crown, Stacey Long, Howard Lee, Xue Song, Stan Finkelstein (2005)
The economic burden of anemia in cancer patients receiving chemotherapy.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 8 2
L. Bastit, A. Vandebroek, S. Altıntaş, B. Gaede, T. Pintér, T. Suto, T. Mossman, Kay Smith, J. Vansteenkiste (2008)
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
K. Knight, S. Wade, L. Balducci (2004)
Prevalence and outcomes of anemia in cancer: a systematic review of the literature.The American journal of medicine, 116 Suppl 7A
E. Akl, F. Doormaal, M. Barba, Ganesh Kamath, Seoyoung Kim, S. Kuipers, S. Middeldorp, Victor Yosuico, H. Dickinson, H. Schünemann (2007)
Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation.The Cochrane database of systematic reviews, 3
W. Brown, P. Maxwell, A. Graham, A. Yakkundi, E. Dunlop, Zhanzhong Shi, P. Johnston, T. Lappin (2007)
Erythropoietin Receptor Expression in Non‐Small Cell Lung Carcinoma: A Question of Antibody SpecificitySTEM CELLS, 25
J. Bohlius, Jayne Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, C. Bennett, Simon Langensiepen, C. Hyde, A. Engert (2006)
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.Journal of the National Cancer Institute, 98 10
G. Curt, W. Breitbart, D. Cella, J. Groopman, S. Horning, L. Itri, David Johnson, C. Miaskowski, S. Scherr, R. Portenoy, N. Vogelzang (2000)
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.The oncologist, 5 5
G. Semenza (2004)
Intratumoral hypoxia, radiation resistance, and HIF-1.Cancer cell, 5 5
B. Teicher, S. Holden, A. Al-Achi, T. Herman (1990)
Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.Cancer research, 50 11
M. Hardee, M. Arcasoy, K. Blackwell, J. Kirkpatrick, M. Dewhirst (2006)
Erythropoietin Biology in CancerClinical Cancer Research, 12
G. Acs, P. Ács, S. Beckwith, R. Pitts, Emily Clements, Kondi Wong, A. Verma (2001)
Erythropoietin and erythropoietin receptor expression in human cancer.Cancer research, 61 9
P. Stohlawetz, L. Dzirlo, N. Hergovich, E. Lackner, C. Mensik, H. Eichler, E. Kabrna, K. Geissler, B. Jilma (2000)
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans.Blood, 95 9
J. Bohlius, Simon Langensiepen, G. Schwarzer, J. Seidenfeld, Margaret Piper, C. Bennet, A. Engert (2004)
Erythropoietin for patients with malignant disease.The Cochrane database of systematic reviews, 3
A. Sinclair, Marque Todd, K. Forsythe, S. Knox, S. Elliott, C. Begley (2007)
Expression and function of erythropoietin receptors in tumorsCancer, 110
A. Anagnostou, E. Lee, N. Kessimian, Rachel Levinson, M. Steiner (1990)
Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.Proceedings of the National Academy of Sciences of the United States of America, 87
J. Crawford, F. Robert, M. Perry, C. Belani, Denise Williams (2007)
A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line ChemotherapyJournal of Thoracic Oncology, 2
M. Hedenus, G. Birgegard, P. Näsman, L. Ahlberg, T. Karlsson, B. Lauri, J. Lundin, G. Lärfars, A. Österborg (2008)
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter studyLeukemia, 22
J. Bohlius, Jayne Wilson, J. Seidenfeld, Margret Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, S. Brunskill, B. Djulbegovic, Charles Bennett, Simon Langensiepen, C. Hyde, A. Engert (2006)
Erythropoietin or darbepoetin for patients with cancer.The Cochrane database of systematic reviews, 3
(2002)
Articles on similar topics can be found in the following Blood collections
H. Ludwig (2004)
rHuEPO and treatment outcomes: the preclinical experience.The oncologist, 9 Suppl 5
E. Akl, Ganesh Kamath, S. Kim, Victor Yosuico, M. Barba, I. Terrenato, F. Sperati, Holger Schünemann (2007)
Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review.Journal of experimental & clinical cancer research : CR, 26 2
D. Henry, N. Dahl, M. Auerbach, S. Tchekmedyian, L. Laufman (2007)
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.The oncologist, 12 2
T. Littlewood, E. Bajetta, J. Nortier, E. Vercammen, B. Rapoport (2001)
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 11
M. Hardee, Yiting Cao, P. Fu, Xiaohong Jiang, Yulin Zhao, Z. Rabbani, Ž. Vujašković, M. Dewhirst, M. Arcasoy (2007)
Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and ProgressionPLoS ONE, 2
M. Aapro, R. Leonard, A. Barnadas, M. Marangolo, M. Untch, N. Malamos, J. Mayordomo, D. Reichert, J. Pedrini, Lidia Ukarma, A. Scherhag, H. Burger (2008)
Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 4
M. Um, Gwyneth Van, G. Begley, S. Elliott, L. Busse, M. Bass, Hsieng Lu, I. Sarosi, A. Sinclair, C. Spahr (2006)
Anti-Epo receptor antibodies do not predict Epo receptor expression.Blood, 107 5
Carole Miller, Richard Jones, S. Piantadosi, M. Abeloff, J. Spivak (1990)
Decreased erythropoietin response in patients with the anemia of cancer.The New England journal of medicine, 322 24
P. Solár, L. Feldman, Jee-Yeong Jeong, Jacqueline Busingye, A. Sytkowski (2008)
Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel‐resistant phenotypeInternational Journal of Cancer, 122
P. Pedrazzoli, A. Farris, S. Prete, F. Gaizo, D. Ferrari, C. Bianchessi, G. Colucci, A. Desogus, T. Gamucci, A. Pappalardo, G. Fornarini, P. Pozzi, A. Fabi, R. Labianca, F. Costanzo, S. Secondino, E. Crucitta, F. Apolloni, A. Santo, S. Siena (2008)
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
Wei Zhao, C. Kitidis, M. Fleming, H. Lodish, S. Ghaffari (2006)
Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway.Blood, 107 3
J. Glaspy (2005)
The development of erythropoietic agents in oncologyExpert Opinion on Emerging Drugs, 10
José Chang, F. Couture, S. Young, Kara McWatters, C. Lau (2005)
Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 12
M. Arcasoy, K. Amin, S. Chou, Z. Haroon, M. Varia, J. Raleigh (2005)
Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 1
S. Rivera, Lide Liu, E. Nemeth, V. Gabayan, O. Sørensen, T. Ganz (2005)
Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia.Blood, 105 4
N. Casadevall, J. Nataf, B. Virón, A. Kolta, J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, P. Mayeux (2002)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.The New England journal of medicine, 346 7
J. Glaspy, R. Bukowski, D. Steinberg, C. Taylor, S. Tchekmedyian, S. Vadhan-Raj (1997)
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 3
A. Sinclair, Norma Rogers, L. Busse, I. Archibeque, W. Brown, Paul Kassner, J. Watson, G. Arnold, Ken Nguyen, Scott Powers, S. Elliott (2008)
Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cellsBritish Journal of Cancer, 98
P. Shekelle, S. Newberry, M. Maglione, R. Shanman, Breanne Johnsen, Jason Carter, Aneesa Motala, Ben Hulley, Zhen Wang, D. Bravata, Michael Chen, J. Grossman (2009)
[Table, CER 3 - Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment].
David Cella, J. Kallich, Anne McDermott, X. Xu (2004)
The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials.Annals of oncology : official journal of the European Society for Medical Oncology, 15 6
M. Dvm (1998)
Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcomeInternational Journal of Radiation Oncology Biology Physics
G. Chertow, P. Mason, Odd Vaage-Nilsen, J. Ahlmén (2006)
Update on adverse drug events associated with parenteral iron.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 21 2
J. Dunst, T. Kuhnt, H. Strauß, U. Krause, T. Pelz, H. Koelbl, G. Haensgen (2003)
Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis.International journal of radiation oncology, biology, physics, 56 3
D. Ribatti, M. Presta, A. Vacca, R. Ria, R. Giuliani, P. Dell’Era, B. Nico, L. Roncali, F. Dammacco (1999)
Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.Blood, 93 8
M. Henke, R. Laszig, C. Rübe, U. Schäfer, K. Haase, B. Schilcher, S. Mose, K. Beer, Ulrich Burger, Chris Dougherty, H. Frommhold (2003)
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 362
P. Vaupel, O. Thews, A. Mayer, S. Höckel, M. Höckel (2002)
Oxygenation Status of Gynecologic Tumors: What is the Optimal Hemoglobin Level?Strahlentherapie und Onkologie, 178
H. Zhong, A. Marzo, E. Laughner, M. Lim, D. Hilton, D. Zagzag, P. Buechler, W. Isaacs, G. Semenza, J. Simons (1999)
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.Cancer research, 59 22
Robert Smith, M. Aapro, H. Ludwig, T. Pintér, M. Šmakal, T. Ciuleanu, Li Chen, T. Lillie, J. Glaspy (2008)
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 7
G. Acs, Mei Chen, Xiaowei Xu, P. Ács, A. Verma, C. Koch (2004)
Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells.Cancer letters, 214 2
James Wright, Y. Ung, J. Julian, K. Pritchard, T. Whelan, Colum Smith, B. Szechtman, W. Roa, L. Mulroy, L. Rudinskas, B. Gagnon, G. Okawara, M. Levine (2007)
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 9
V. Charu, C. Belani, A. Gill, M. Bhatt, D. Tomita, G. Rossi, A. Ben-Jacob (2007)
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.The oncologist, 12 6
G. Semenza (2000)
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor ProgressionCritical Reviews in Biochemistry and Molecular Biology, 35
Therapy with erythropoiesis-stimulating agents (ESAs) is associated with well-documented benefits to anemic cancer patients undergoing chemotherapy, most importantly a reduction in the likelihood of needing red cell transfusions. One challenge in supportive cancer care is a relative resistance to ESAs, requiring high doses with a significant rate of nonresponse. Recent advances in our understanding of iron metabolism in patients with chronic illness and the results of clinical trials indicate that parenteral iron improves ESA response in this setting. Another issue is the safety of ESA treatment in cancer patients. There is an increased risk of venous thrombosis that must be considered in clinical decision making. There are also recent data raising concerns that ESAs may enhance tumor progression or decrease patient survival. Although the preponderance of the data suggests that ESAs do not alter survival when used to treat chemotherapy-induced anemia, large well-controlled trials addressing this issue are needed.
Annual Review of Medicine – Annual Reviews
Published: Feb 18, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.